Cellectar Biosciences (CLRB) Competitors $4.88 +0.39 (+8.69%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$4.82 -0.06 (-1.23%) As of 08/22/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLRB vs. MURA, MAAQ, CASI, TRIB, KZR, JATT, MIRA, RNTX, TENX, and DYAIShould you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include Mural Oncology (MURA), Mana Capital Acquisition (MAAQ), CASI Pharmaceuticals (CASI), Trinity Biotech (TRIB), Kezar Life Sciences (KZR), JATT Acquisition (JATT), MIRA Pharmaceuticals (MIRA), Rein Therapeutics (RNTX), Tenax Therapeutics (TENX), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry. Cellectar Biosciences vs. Its Competitors Mural Oncology Mana Capital Acquisition CASI Pharmaceuticals Trinity Biotech Kezar Life Sciences JATT Acquisition MIRA Pharmaceuticals Rein Therapeutics Tenax Therapeutics Dyadic International Mural Oncology (NASDAQ:MURA) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends. Do analysts rate MURA or CLRB? Mural Oncology currently has a consensus price target of $12.00, indicating a potential upside of 476.92%. Cellectar Biosciences has a consensus price target of $375.00, indicating a potential upside of 7,584.43%. Given Cellectar Biosciences' higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Mural Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Cellectar Biosciences 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is MURA or CLRB more profitable? Mural Oncology's return on equity of -107.76% beat Cellectar Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Mural OncologyN/A -107.76% -87.57% Cellectar Biosciences N/A -486.67%-150.57% Which has more risk and volatility, MURA or CLRB? Mural Oncology has a beta of 3, indicating that its stock price is 200% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Does the media favor MURA or CLRB? In the previous week, Mural Oncology had 6 more articles in the media than Cellectar Biosciences. MarketBeat recorded 6 mentions for Mural Oncology and 0 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.16 beat Mural Oncology's score of 0.16 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Mural Oncology Neutral Cellectar Biosciences Neutral Do institutionals and insiders believe in MURA or CLRB? 80.2% of Mural Oncology shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 2.2% of Mural Oncology shares are held by insiders. Comparatively, 5.0% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, MURA or CLRB? Cellectar Biosciences is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMural OncologyN/AN/A-$128.51M-$8.59-0.24Cellectar BiosciencesN/AN/A-$44.58M-$19.91-0.25 SummaryMural Oncology beats Cellectar Biosciences on 7 of the 11 factors compared between the two stocks. Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLRB vs. The Competition Export to ExcelMetricCellectar BiosciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.33M$10.84B$5.76B$9.58BDividend YieldN/A1.87%4.41%4.10%P/E Ratio-0.2520.9031.1026.05Price / SalesN/A29.66435.79105.95Price / CashN/A24.5537.7358.48Price / Book2.803.519.536.61Net Income-$44.58M$211.77M$3.26B$265.56M7 Day Performance12.44%4.44%2.09%1.97%1 Month Performance-12.70%8.85%2.81%-0.36%1 Year Performance-92.33%-9.03%30.56%19.03% Cellectar Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLRBCellectar Biosciences2.2749 of 5 stars$4.88+8.7%$375.00+7,584.4%-92.2%$14.33MN/A-0.2510MURAMural Oncology3.0017 of 5 stars$1.82+3.4%$12.00+559.3%-36.6%$30.49MN/A-0.21119MAAQMana Capital AcquisitionN/A$3.63-9.8%N/A+727.6%$29.49MN/A0.001CASICASI Pharmaceuticals3.7322 of 5 stars$2.26-5.0%$4.00+77.0%-65.0%$29.27M$28.54M-0.89180Gap DownTRIBTrinity Biotech1.5086 of 5 stars$1.57-3.1%N/A-29.6%$29.25M$61.56M-0.54480Upcoming EarningsGap DownKZRKezar Life Sciences3.8639 of 5 stars$3.86-2.8%$9.00+133.2%-33.6%$29.07M$7M-0.4060High Trading VolumeJATTJATT AcquisitionN/A$1.66-3.5%N/A-43.8%$28.64MN/A0.003Gap UpHigh Trading VolumeMIRAMIRA Pharmaceuticals3.0737 of 5 stars$1.48-1.3%$17.00+1,048.6%-23.5%$28.60MN/A-3.022RNTXRein TherapeuticsN/A$1.13-5.4%N/AN/A$27.52MN/A0.009News CoverageAnalyst DowngradeTENXTenax Therapeutics1.6686 of 5 stars$6.01+0.7%$17.00+182.9%+39.2%$27.24MN/A-6.539DYAIDyadic International3.4956 of 5 stars$0.80+6.3%$6.00+654.6%-38.0%$27.08M$3.49M-4.187Gap Up Related Companies and Tools Related Companies MURA Alternatives MAAQ Alternatives CASI Alternatives TRIB Alternatives KZR Alternatives JATT Alternatives MIRA Alternatives RNTX Alternatives TENX Alternatives DYAI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLRB) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access